


AMENDMENTS TO THE CLAIMS


Claims 1 - 28 (previously canceled)

Claim 29 (currently amended)


A carbohydrate peptide conjugate comprising a dendrimeric poly-lysine carrier enabling multiple epitopes B and T to be covalently attached thereto, wherein said carbohydrate peptide conjugate is selected from the group consisting of the conjugates of the following formulae




(B4-T4-M)



(B2-T2-M)



(B6-T6-M)



wherein:

- B denotes a structurally defined carbohydrate moiety which is a tumor antigen, or a derivative thereof, containing B epitope other than a ~~sialoside~~ sialoside, or several identical or different B epitopes;
- T denotes a peptide comprising one CD4⁺ T epitope or several identical or different T-epitopes;
- K denotes a lysine ~~from 1 to 13~~ residue;
- n is an integer from 1 to 13;
- m is an integer from 1 to 9; and

wherein the B and T groups are covalently attached to the poly-lysine carrier.

Claim 30 (original)

A conjugate of claim 29 wherein the carbohydrate moiety is galactosyl.

Claim 31 (currently amended)

A conjugate of claim 29 which comprises 3 lysine residues, at least 2 CD4⁺ T cell epitopes, which may be the same or different, linked to the NH₂ ends of 2 of the lysine residues and 4 α-galactosyl-N-acetyl-Serine residues.

Claim 32 (previously amended)

A conjugate of claim 29 wherein the carbohydrate moiety is a galactosyl residue and is substituted with a glycosyl residue.

Claims 33 – 35 (previously cancelled)

Claims 36 – 37 (previously cancelled)

Claim 38 (previously added)

A conjugate of claim 29 wherein the carbohydrate is selected from the group consisting of Tn antigen, di-Tn antigen, Tri-Tn antigen, T^{*} antigen and hexa-Tn antigen.

Claim 39 (previously added)

A pharmaceutical composition comprising the conjugate of claim 29 and a suitable carrier and adjuvant.

Claim 40 (previously added)

A vaccine comprising the conjugate of claim 29.

Claim 41 (previously cancelled)

Claim 42 (previously added)

An immunogenic composition comprising at least one carbohydrate peptide conjugate of claim 29 wherein said composition is capable of increasing the survival of a tumor bearing human or animal.

Claim 43 (currently amended)

21
An immunogenic composition comprising at least one carbohydrate conjugate of claim 42 wherein said conjugate comprises different carbohydrate antigens to induce more efficient anti-tumor immunity against cancers.

Claim 44 (currently amended)

A method of inducing an immune response to at least one member of the group consisting of B-cells and CD4⁺ T-cells in a human or animal body, wherein the conjugate of claim 29 is administered to said human or animal body.

Claims 45 and 46 (previously cancelled)

Claim 47 (previously added)

A method of vaccination of a human or animal body wherein the conjugate of claim 29 is administered to said human or animal body.

2/2
2012